Back to the main directory
EarningsReview / Equity
- Chevron (CVX US) by HSBC
- Shell (SHEL LN) by HSBC
- Scatec - Buy/NOK 106 (110): Doing all the right things by Nordea
- Tenant uncertainty likely to linger; d/g to Underperform by BNP Paribas Exane
- Sustainability Weekly 28 – 31 octobre 2024 by Oddo BHF
- Construction Compass: November edition by BNP Paribas Exane
- Trump vs Harris: The Final Countdown by BNP Paribas Exane
- 3Q24 Results - what to expect? by BNP Paribas Exane
- Investor Day 2024: Nothing burger or a big deal? by BNP Paribas Exane
- by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Put aside the Fed. It’s all about margins - presentation by BNP Paribas Exane
- Trifork - Q3 24 – A surprisingly large miss by Danske Bank Equity Research
- INVEST SECURITIES - NACON : T2 24/25 rassurant, mais le problème reste à traiter - ACHAT, OC 1,9€ by Invest Securities
- INVEST SECURITIES - VALBIOTIS : S1 24 conforme, visibilité faible sur les perspectives - ACHAT, OC 3,0€ vs 5,0€ by Invest Securities
- U10 - Presque Satisfaisant by MidCap Partners
- Prosegur - Stronger Security drives 3Q24 EBITA beat; Buy by JB Capital Markets
- Advanced Info Service (ADVANC TB) by HSBC
- Meningitis panel approval makes US menu competitive by BNP Paribas Exane
- INVEST SECURITIES - TME PHARMA : 7m€ de subventions garanties, reste 18m€ à lever - ACHAT, OC 0,49€ by Invest Securities
- MT, CMC, CLF, US REBAR, US AUTO, ELECTIONS, ESG by BNP Paribas Exane
- U10 - Almost satisfactory. by MidCap Partners
- AFT Pharmaceuticals - H125 profitability weighed down by one-offs by Edison Investment Research
- Q3 24 post view by BNP Paribas Exane
- 五粮液（000858 CH） by HSBC
- Kalmar - Recovery may take time, but potential for big rewards by Danske Bank Equity Research
- Humble Group - Buy/SEK 15: Positive signs from several fronts by Nordea
- Fertile thoughts by BNP Paribas Exane
- 3Q24 Results - what to expect? by BNP Paribas Exane
- Kalmar - Hold (Buy/EUR 32): Share price rise makes for a balanced risk/reward by Nordea
- Sustainability Weekly 28 – 31 October 2024 by Oddo BHF
- Q3’24 postview: ask silly questions, get silly answers by BNP Paribas Exane
- Q3’24 preview: acceleration expected across the board. by BNP Paribas Exane
- Disappointing quarter by BNP Paribas Exane
- Expect a tough H1, followed by improving profitability by BNP Paribas Exane
- Sell-off looks overdone by BNP Paribas Exane
- Intesa Sanpaolo - PAVING THE GROUND FOR ANOTHER STRONG YEAR by Equita Sim
- Investor Day: First Take by BNP Paribas Exane
- INVEST SECURITIES - BIGBEN : Bon T2 mais à l'impact limité sur le refinancement - ACHAT, OC 3€ by Invest Securities
- MedinCell - Confirmation des bons résultats en schizophrénie by MidCap Partners
- INVEST SECURITIES - CAPGEMINI : Le retour du momentum repoussé à 2025 - ACHAT, OC 240€ by Invest Securities
- INVEST SECURITIES - BIOMERIEUX : Vers un haut de fourchette de guidance - ACHAT, OC 130€ (vs 126€) by Invest Securities
- CMS increases ESRD PPS rate by 2.7% by BNP Paribas Exane
- INVEST SECURITIES - SOPRA STERIA : Profil résistant confirmé, valorisation trop faible - ACHAT, OC 266€ by Invest Securities
- CEO replaced; is Blum the superstar that Schneider needs? by BNP Paribas Exane
- Discussions with Meta moving from stake to board seat by BNP Paribas Exane
- MedinCell - Confirmation of positive results in schizophrenia by MidCap Partners
- Tubacex - 3Q24 EBITDA in line, positive outlook is reassuring; Buy by JB Capital Markets
- Decent trends, awaiting acquisition/buyback decisions by BNP Paribas Exane
- Wuliangye (000858 CH) by HSBC